Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.

We conducted a Phase I randomized, dose-escalation, route-comparison trial of MVA-CMDR, a candidate HIV-1 vaccine based on a recombinant modified vaccinia Ankara viral vector expressing HIV-1 genes env/gag/pol. The HIV sequences were derived from circulating recombinant form CRF01_AE, which predomin...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Jeffrey R Currier, Viseth Ngauy, Mark S de Souza, Silvia Ratto-Kim, Josephine H Cox, Victoria R Polonis, Patricia Earl, Bernard Moss, Sheila Peel, Bonnie Slike, Somchai Sriplienchan, Prasert Thongcharoen, Robert M Paris, Merlin L Robb, Jerome Kim, Nelson L Michael, Mary A Marovich
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Public Library of Science (PLoS) 2010-11-01
Serie:	PLoS ONE
Länkar:	http://europepmc.org/articles/PMC2981570?pdf=render
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!